Press Releases

BioSavita Wins Top Award at GLEQ Competition

Sep 19, 2013 in Press Releases

BioSavita Inc. was the winner of the Great Lakes Entrepreneur’s award at Entrepreneur Connect in Lansing in June 2013. They received the $100,000 SmartZone Award for its yeast technology to produce biopharmaceutical drugs. Read the entire article

BioSavita and Quanta BioDesign Collaborate to Develop Novel Biological Drugs With Enhanced Activity

May 14, 2013 in Press Releases

PLYMOUTH, MI and POWELL, OH–(Marketwired – Apr 29, 2013) – BioSavita and Quanta BioDesign, announced today a collaboration to develop BioSuperior XL™ therapeutics, which are novel, sildenafil sources natural biological drugs based on proven clinical mechanisms, but with an improved drug profile. The collaboration unites the strengths of the two companies’ proprietary drug development technologies. BioSavita’s genetically engineered strains of Saccharomyces cerevisiae yeast and Twin Cassette™ yeast...

BioSavita Named Top Life Sciences Company at Largest Business Plan Competition in North America

Mar 14, 2013 in Press Releases

March 14, 2013 Plymouth, MI – BioSavita announced today that Accelerate Michigan named it the top life sciences company in its annual business plan competition. The Accelerate Michigan Innovation Competition is the largest business plan competition in North America and annually awards $1 million in prize money. Accelerate Michigan’s investor judges reviewed more than 300 business plans, selected 50 semifinalists and selected 10 finalists after pitches were made. “The BioSavita team is honored and humbled to receive this...

BioSavita Appoints James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer

Sep 27, 2012 in Press Releases

September 27, 2012 BioSavita, Inc. announced today that its board has appointed James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer. He plans to lead the company’s growth through development of its portfolio of biosimilar products and additional corporate partners for its Twin Cassette® yeast expression technology, which allows rapid production of fully functional antibodies in secreted form. Dr. Kuo has over 20 years of life science industry experience as a venture capitalist, pharmaceutical business development executive and...

BioSavita Named Semifinalist in Accelerate Michigan Innovation Competition

Sep 22, 2012 in Press Releases

September 2012 BioSavita is a biotechnology company focused on accelerating therapeutic antibody development for our Antibodies are the newest pharmaceutical blockbusters with $56 billion in aggregate sales in 2011 growing at 13–15% CAGR to over $70B by 2015. BioSavita’s CEO has successfully led venture-backed as well as publicly traded biotech team includes two of the top-licensing professionals for antibody expression platforms. The company has developed and validated its Twin Cassette™ yeast expression platform technology....

BioSavita Awarded a Grant from Qualified Tax Discovery Project Program

Nov 22, 2010 in Press Releases

November 2010 The Qualifying Tax Discovery Project (QTDP), canadian pharmacy wellbutrin xl 300 mg by the IRS, awards credits or grants sms tracker agent online for projects that show significant potential to produce new cost-saving therapies, creates U.S. jobs and increases national competition for such therapies. ApoLife received a grant of $200,000 from the QTDP to support initial work on the company’s program to generate and develop a novel antibody –secretory IgA (sIgA) for mucosal therapy of C.difficile infections...